Coya Therapeutics, Inc. SEC Filings

Coya Therapeutics, Inc. received an updated ownership report on its common stock from investor Orin Hirschman and affiliated entities on a Schedule 13G/A (Amendment No. 3).

Mr. Hirschman reports beneficial ownership of 1,108,171 shares, representing 5.3% of Coya’s common stock, with sole voting and dispositive power over these shares. AIGH Capital Management LLC reports beneficial ownership of 975,404 shares, representing 4.7% of the class, also with sole voting and dispositive power. The filing is made on a passive basis, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coya Therapeutics.

Coya Therapeutics reported that its Chief Financial Officer, David S. Snyder, received a grant of stock options on January 22, 2026. The award covers 140,041 stock options, each giving the right to buy one share of common stock at an exercise price of $4.73 per share.

The options vest in monthly installments over 36 months, as long as the executive continues to serve through each vesting date. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

Coya Therapeutics, Inc. reported that Chief Medical Officer Fred Grossman received a grant of stock options to purchase 140,041 shares of common stock at an exercise price of $4.73 per share. The options were awarded at no cash cost at grant and are held directly. Subject to continuous service, the shares underlying the option vest in monthly installments over the next 36 months. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended effective November 17, 2022.

Coya Therapeutics, Inc. reported that Executive Chairman Howard Berman received a stock option grant on 01/22/2026. The option gives him the right to buy 15,257 shares of common stock at an exercise price of $4.73 per share.

These options vest in monthly installments over the next 36 months, as long as he remains in continuous service through each vesting date. The filing also states that if there is a change in control of the company, all unvested shares under this option will vest and the option will become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended in November 2022.

Coya Therapeutics, Inc. reported a new equity award to its Chief Executive Officer, Swaminathan Arun. On January 22, 2026, he received a stock option covering 293,983 shares of common stock with an exercise price of $4.73 per share.

These options were granted at a price of $0 for the derivative itself and are held directly. The shares underlying the option vest in monthly installments over 36 months, conditioned on continued service. If there is a change in control of Coya Therapeutics, all unvested shares under this option will vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

Coya Therapeutics, Inc. filed a current report describing a stockholder letter that updates its financial position and key clinical milestone timing. The company reported an unaudited cash balance of $46.8 million as of December 31, 2025, and stated it has a projected cash runway into the second half of 2027, indicating it currently expects to fund operations for an extended period. Coya also noted that it expects a topline data readout from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027, giving investors a timeframe for when important clinical results may become available.

Coya Therapeutics reported early clinical data from an investigator-initiated, open-label proof-of-concept study using a combination of low-dose IL-2 and CTLA4-Ig in 9 patients with Frontotemporal Dementia over about six months. Patients received subcutaneous CTLA4-Ig plus a 5-day course of low-dose IL-2 every four weeks for a total of 22 weeks of dosing and follow-up.

The treatment was generally well tolerated: the most common side effect was mild injection-site redness in 33.3% of individuals, and no serious adverse events were observed. Measures of regulatory T cell (Treg) activity and markers such as CD25 and FOXP3 showed significant increases as early as two weeks after dosing and remained elevated through week 22.

Cognitive outcomes, measured by Montreal Cognitive Assessment and CDR-FTLD scores, were essentially stable from baseline (MOCA 13.5; CDR-FTLD 4.8) to week 22 (MOCA 14; CDR-FTLD 5.5), suggesting no notable decline in cognitive or functional status over the treatment period in this small group.

Coya Therapeutics director Anabella Villalobos received a grant of stock options covering 10,000 shares of common stock. The options were granted on January 2, 2026 with an exercise price of $5.65 per share and no cost to receive the award. The filing reports that Villalobos now beneficially owns 10,000 derivative securities directly.

According to the vesting terms, 100% of the option will vest on the first anniversary of the grant date, as long as continuous service is maintained. The options are scheduled to expire on January 2, 2036 if not exercised.

Coya Therapeutics, Inc. reported that director Wilbur L. Ross Jr. received a new stock option award. On January 2, 2026, he was granted a stock option to buy 10,000 shares of Coya common stock at an exercise price of $5.65 per share. The option was granted at no cost and is held directly.

Subject to his continuous service, 100% of the option will vest on the first anniversary of the grant date, meaning it becomes fully exercisable after one year. The option is scheduled to expire on January 2, 2036 if not exercised. Following this grant, he beneficially owns 10,000 derivative securities in the form of this option.